Loading
Thalidomide and its descendants lenalidomide and pomalidomide, which hijack a cellular waste-disposal tag (cereblon) to destroy two proteins myeloma cells depend on, while also revving up T and NK cells. CELMoDs such as iberdomide and mezigdomide bind cereblon more tightly and work after lenalidomide fails; clots, low blood counts and birth defects are class risks.
Thalidomide's return from the 1960s disaster as a myeloma drug (1999) and the discovery that it acts as a molecular glue degrader of IKZF1/3 via cereblon founded the whole field of targeted protein degradation. Lenalidomide is in nearly every myeloma induction and maintenance regimen and treats del(5q) MDS and some lymphomas; pomalidomide follows lenalidomide failure. CELMoDs (iberdomide, mezigdomide) bind cereblon more tightly and are active in lenalidomide-refractory disease (EXCALIBER). Class effects are cytopenias, thrombosis (prophylaxis required), rash, and secondary cancers; teratogenicity mandates pregnancy-prevention programmes.
Showing the molecule this term concerns: Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Pomalidomide, Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide.
Shares Thalidomide, Molecular glue discovery platforms, Pomalidomide, Lenalidomide.
Shares Molecular glue discovery platforms, Pomalidomide, Lenalidomide, Relapsed or refractory multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.